Atai Life Sciences and Beckley Psytech Limited announced encouraging Phase 2b trial results and plans to engage the FDA regarding Phase 3 trial design.

The entities involved

• Atai Life Sciences →

  German pharmaceutical company

  • Atai Life Sciences, a German-headquartered company, is seeking FDA meetings and study results while benefiting from Trump-era tariffs.Sun 03:45
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.Sep 15
• SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.Sep 7
• The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.Aug 26
• NewcelX Ltd. advanced its IND-enabling work for a Phase 1/2a trial and held a successful Type B Pre-IND meeting with the FDA.Mon 14:50
• Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.Sep 14